Brief: Klaria Pharma Holding AB (Publ) - Enters Option Agreement With Imbrium Therapeutics

Klaria Pharma Holding AB (publ)

22/03/2021 15:51

March 22 (Reuters) - Klaria Pharma Holding AB (publ)  KLAR.ST :
    * KLARIA PHARMA HOLDING AB (PUBL) - ENTERS OPTION AGREEMENT WITH IMBRIUM THERAPEUTICS
REGARDING
MARKET RIGHTS IN THE US FOR DRUG CANDIDATE
    * KLARIA PHARMA HOLDING AB (PUBL) - DRUG CANDIDATE EPINEPHRINE ALGINATE FILM IS BEING
DEVELOPED AS
A TREATMENT FOR SERIOUS ALLERGIC REACTIONS, SO CALLED ANAPHYLACTIC SHOCK, AS AN ALTERNATIVE TO
CURRENTLY AVAILABLE TREATMENT OPTIONS INCLUDING EPIPEN
    * KLARIA PHARMA HOLDING AB (PUBL) HAS RECEIVED AN UPFRONT OPTION PAYMENT OF USD 3.5 MILLION
(SEK
30 MILLION)
    * KLARIA PHARMA HOLDING AB (PUBL) - SHOULD IMBRIUM EXERCISE ITS OPTION, KLARIA WILL BE
ELIGIBLE TO
GET CONTINGENT MILESTONE PAYMENTS WITH TOTAL VALUE UP TO USD 66,5 MILLION (SEK 560 MILLION) AND
A DOUBLE-DIGIT ROYALTY ON THE US NET SALES OF EPINEPHRINE ALGINATE FILM

Source text for Eikon:  ID:nWkr6bprxm 
Further company coverage:  KLAR.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))